Treatment of gastrointestinal stromal tumor: Focus on imatinib mesylate

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 149-162

  Din, Omar S ^a   Wool, Penella J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Gastrointestinal; GIST; Imatinib; STI 571; Stromal; Tumor

Indexed keywords

ALPHA INTERFERON; ALPRAZOLAM; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BEVACIZUMAB; CEDIRANIB; CLINDAMYCIN; CLONAZEPAM; DASATINIB; DOXORUBICIN; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUCONAZOLE; FLUORODEOXYGLUCOSE F 18; HYDROCORTISONE; IFOSFAMIDE; IMATINIB; MIDOSTAURIN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PARACETAMOL; PLACEBO; RIFAMPICIN; SIMVASTATIN; SORAFENIB; SUNITINIB; THALIDOMIDE; TRABECTEDIN; UNINDEXED DRUG; VATALANIB; VERAPAMIL;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; GRANULOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LETHARGY; LEUKOPENIA; LIVER METASTASIS; MUTATIONAL ANALYSIS; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PERITONEUM METASTASIS; PROGNOSIS; PROTEIN TARGETING; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; STOMACH PAIN; TUMOR VOLUME; VOMITING;

EID: 41549090876     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Antoch G, Kanja J, Bauer S, et al. 2004. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med, 45:357-65.
2. Antonescu CR, Besmer P, Guo T, et al. 2005. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res, 11:4182-90.
3. Bauer S, Hartmann JT, De Wit M, et al. 2005. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer, 117:316-25.
4. Bauer S, Yu LK, Demetri GD, et al. 2006. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res, 66:9153-61.
5. Benjamin RS, Blanke CD, Blay JY, et al. 2006. Management of gastro-intestinal stromal tumors in the imatinib era: selected case studies. Oncologist, 11:9-20.
6. Benjamin RS, Choi H, Macapinlac HA, et al. 2007. We should desist using RECIST, at least in GIST. J Clin Oncol, 25:1760-4.
7. Benjamin RS, Rankin C, Fletcher C, et al. 2003. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol, 22.
8. Berindoague R, Targarona EM, Feliu X, et al. 2006. Laparoscopic resection of clinically suspected gastric stromal tumors. Surg Innov, 13:231-7.
9. Bertucci F, Goncalves A, Monges G, et al. 2006. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour. Oncol Rep, 16:97-101.
10. Blanke C, Joensuu H, Demetri G, et al. 2004. Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. Proc Am Soc Clin Oncol GI Cancer Symposium, 2.
11. Blay JY, Bonvalot S, Casali P, et al. 2005. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.[erratum appears in Ann Oncol. 2005 Jun; 16(6):993 Note: Mac Clure, J [corrected to McClure, [J]. Ann Oncol, 16:566-78.
12. Blay JY, Le Cesne A, Ray-Coquard I, et al. 2007. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol, 25:1107-13.
13. Bucher P, Egger JF, Gervaz P, et al. 2006. An audit of surgical management of gastrointestinal stromal tumours (GIST). Eur J Surg Oncol, 32:310-4.
14. Burger H, Den Bakker MA, Kros JM, et al. 2005. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatimb mesylate target genes.[see comment]. Cancer Biol Ther, 4:1270-4.
15. Carney JA, Sheps SG, Go VL, et al. 1977. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med, 296:1517-8.
16. Carroll M, Ohno-Jones S, Tamura S, et al. 1997. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood, 90:4947-52.
17. Chen H, Pruitt A, Nicol TL, et al. 1998. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg, 2:151-5.
18. Choi H, Charnsangavej C, Faria SC, et al. 2007. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol, 25:1753-9.
19. Corless CL, Fletcher JA, Heinrich MC. 2004. Biology of gastrointestinal stromal tumors. J Clin Oncol, 22:3813-25.
20. D'Amato G, Steinert DM, McAuliffe JC, et al. 2005. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control, 12, 44-56.
21. DeGiorgi U, and Verweij J. (2005) Imatinib and gastrointestinal stromal tumors: Where do we go from here? Mol Cancer Ther, 4:495-501.
22. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, et al. 2001. Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet, 128:24-30.
23. Debiec-Rychter M, Sciot R, Le Cesne A, et al. 2006. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer, 42:1093-103.
24. DeMatteo R, Owzar K, Maki R, et al.; ACOSOG AIAGS. 2007. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001, 2007 ASCO Annual Meeting, 10079.
25. DeMatteo RP, Heinrich MC, El-Rifai WM, et al. 2002. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol, 33:466-77.
26. DeMatteo RP, Lewis JJ, Leung D, et al. 2000. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg, 231:51-8.
27. Demetri GD, Van Oosterom AT, Garrett CR, et al. 2006. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 368:1329-38.
28. Demetri GD, Von Mehren M, Blanke CD, et al. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347:472-80.
29. Desai J, Yassa L, Marqusee E, et al. 2006. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med, 145:660-4.
30. Doi T, Nishida T, Hirota S, et al. 2004. Phase II clinical study of ST1571 in Japanese (Jpn) patients (pts) with malignant gastrointestinal stromal tumors (GIST): Results of the B 1201 study. J Clin Oncol, 22:4078.
31. Druker BJ, Talpaz M, Resta DJ, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344:1031-7.
32. Druker BJ, Tamura S, Buchdunger E, et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 2:561-6.
33. Ernst SI, Hubbs AE, Przygodzki RM, et al. 1998. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest, 78:1633-6.
34. Fletcher CD, Berman JJ, Corless C, et al. 2002. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol, 33:459-65.
35. Fletcher JA, Curless CL, Dimitrijevic S, et al. 2003. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol, 22.
36. Goerres GW, Stupp, R, Barghouth G, et al. 2005. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging, 32:153-62.
37. Gunawan B, Bergmann F, Hoer J, et al. 2002. Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Hum Pathol, 33:316-21.
38. Heinrich MC, Corless CL, Demetri GD, et al. 2003a. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol, 21:4342-9.
39. Heinrich MC, Corless CL, Duensing A, et al. 2003b. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 299:708-10.
40. Heinrich MC, Griffith DJ, Druker BJ, et al. (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood, 96:925-32.
41. Hirota S, Isozaki K, Moriyama Y, et al. 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279:577-80.
42. Hirota S, Ohashi A, Nishida T, et al. 2003. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology, 125:660-7.
43. Ishida T, Wada I, Horiuchi H, et al. 1996. Multiple small intestinal stromal tumors with skeinoid fibers in association with neurofibromatosis 1 (von Recklinghausen's disease). Pathol Int, 46:689-95.
44. Joensuu H. 2006. Sunitinib for imatinib-resistant GIST. Lancet, 368:1303-4.
45. Joensuu H, Fletcher C, Dimitrijevic S, et al. 2002. Management of malignant gastrointestinal stromal tumours. Lancet Oncol, 3:655-64.
46. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. 2001. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med, 344:1052-6.
47. Judson I, Ma P, Peng B, et al. 2005. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol, 55:379-86.
48. Kasper B, Kallinowski B, Herrmann T, et al. 2006. Treatment of gastrointestinal stromal tumor with imatinib mosylate: a retrospective single-center experience in Heidelberg. Dig Dis, 24:207-11.
49. Kindblom LG, Remotti HE, Aldenborg F, et al. 1998, Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol, 152:1259-69.
50. King DM. 2005. The radiology of gastrointestinal stromal tumours (GIST). Cancer Imaging, 5:150-6.
51. Kosmadakis N, Visvardis EE, Kartsaklis P, et al. 2005. The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness. Surg Oncol, 14:75-84.
52. Lasota J, Jasinski M, Sarlomo-Rikala M. et al. 1999. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol, 154:53-60.
53. Le Cesne A, Ray-Coquard I, Bui M, et al. 2007. Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings, Part I. 25(18S) (June 20 Supplement):10005.
54. Li SQ, O'Leary TJ, Sobin LH, et al. 2000. Analysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/ smooth muscle tumors. Acta Cytol, 44:981-6.
55. Linton KM, Taylor MB, Radford JA. 2006. Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol, 79:e40-4.
56. Loughrey MB, Mitchell C, Mann GB, et al. 2005. Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol, 58:779-81.
57. Mavligit GM, Zukwiski AA, Ellis LM, et al. 1995. Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer, 75:2083-8.
58. Mazur MT, Clark HB. 1983. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 7:507-19.
59. Miettinen M, Lasota J. 2001. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch, 438:1-12.
60. Miettinen M, Majidi M, Lasota J. 2002. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer, 38:S39-51.
61. Miettinen M, Makhlouf H, Sobin LH, et al. (2006) Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol, 30:477-89.
62. Miettinen M, Sobin LH, Lasota J. 2005. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol, 29:52-68.
63. Miettinen M, Virolainen M, Maarit Sarlomo R. 1995. Gastrointestinal stromal tumors - value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol, 19:207-16.
64. NCI. 2007. GIST clinical trials search [online]. Accessed 5 May 2007. URL: http://www.cancer.gov/search/ ResultsClinicalTrials.aspx?protocolsearchid=2096061.
65. Neuhaus SJ, Clark MA, Hayes AJ, et al. 2005/Surgery for gastrointestinal stromal tumour in the post-imatinib era. ANZ J Surg, 75:165-72.
66. Ng EH, Pollock RE, Munsell MF, et al. 1992. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg, 215:68-77.
67. Nilsson B, Bumming P, Meis-Kindblom JM, et al. 2005. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer, 103:821-9.
68. Novartis. 2005. Glivec (imatinib) Summary of Product Characteristics.
69. Novitsky YW, Kercher KW, Sing RF, et al. 2006. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg, 243:738-45; discussion 745-7.
70. Peng B, Lloyd P, Schran H. 2005. Clinical pharmacokinetics of imatinib. Clin Pharmacokinetics, 44:879-94.
71. Plaat BE, Hollema H, Molenaar WM, et al, 2000. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol, 18:3211-20.
72. Rajan DK, Soulen MC, Clark TW, et al. 2001. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol, 12:187-93.
73. Rankin C, Von Mehren M, Blanke C, et al. 2004. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol, 22.
74. Raut CP, Posner M, Desai J, et al. 2006. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol, 24:2325-31.
75. Rubin BP, Singer S, Tsao C, et al. 2001. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res, 61:8118-21.
76. Rutkowski P, Nowecki ZI, Michej W, et al. 2007. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol, 14:2018-27.
77. Ryu MH, Lee JL, Chang HM, et al. 2006. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. Jpn J Clin Oncol, 36:17-24.
78. Sakakura C, Hagiwara A, Soga K, et al. 2006. Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy. World J Gastroenterol, 12:2793-7.
79. Sanborn RE, Blanke CD. (2005) Gastrointestinal stromal tumors and the evolution of targeted therapy. Clin Adv Hematol Oncol, 3:647-57.
80. Savage DG, Antman KH. 2002. Imatinib mesylate - a new oral targeted therapy. N Engl J Med, 346:683-93.
81. Schindler CG, Armbrust T, Gunawan B, et al. 2005. Gastrointestinal stromal tumor (GIST) - single center experience of prolonged treatment with imatinib. Z Gastroenterol, 43:267-73.
82. Shankar S, Vansonnenberg E, Desai J, et al. 2005. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology, 235:892-8.
83. Sihto H, Sarlomo-Rikala M, Tynninen O, et al. 2005. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol, 23:49-57.
84. Steigen SE, Eide TJ, Wasag B, et al. 2007. Mutations in gastrointestinal stromal tumors - a population-based study from Northern Norway. APMIS, 115:289-98.
85. Stroobants S, Goeminne J, Seegers M, et al. 2003. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). [see comment]. Eur J Cancer, 39:2012-20.
86. Takahashi H, Saitoh K, Kishi H, et al. 1995. Immunohistochemical localisation of stem cell factor (SCF) with comparison of its receptor c-Kit proto-oncogene product (c-KIT) in melanocytic tumours. Virchows Arch, 427:283-8.
87. Taniguchi M, Nishida T, Hirota S, et al. 1999. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res, 59:4297-300.
88. Van Der Zwan SM, Dematteo RP. 2005. Gastrointestinal stromal tumor: 5 years later. Cancer, 104:1781-8.
89. Van Glabbeke M, Verweij J, Casali PG, et al. 2005. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastro-intestinal Trials Group study. J Clin Oncol, 23:5795404.
90. Van Glabbeke MM, Owzar K, Rankin C, et al. (METAGIST), GM-AG. 2007. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings,Part I. 25(18S) (June 20 Supplement):10004.
91. Van Oosterom AT, Judson I, Verweij J, et al. 2001. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet, 358:1421-3.
92. Van Oosterom AT, Judson IR, Verweij J, et al. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma. 2002 Update of phase I study of imatinib (ST1571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer, 38:S83-7.
93. Verweij J, Casali PG, Zalcberg J, et al. 2004. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.[see comment]. Lancet, 364:1127-34.
94. Verweij J, Van Oosterom A, Blay JY, et al. 2003. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.[see comment]. Eur J Cancer, 39:2006-11.
95. Wardelmann E, Hrychyk A, Merkelbach-Bruse S, et al. 2004. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn, 6:197-204.
96. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. 2006. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.[see comment]. Clin Cancer Res, 12:1743-9.
97. Wardelmann E, Thomas N, Merkelbach-Bruse S, et al. 2005. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol, 6:249-51.
98. Went PT, Dirnhofer S, Bundi M, et al. 2004. Prevalence of KIT expression in human tumors. J Clin Oncol, 22:4514-22.
99. West RB, Corless CL, Chen X, et al. 2004. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol, 165:107-13.
100. Wu PC, Langerman A, Ryan CW, et al. 2003. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery, 134:656-65.